bluuebunny/crossref_metadata_2025_split huggingface dataset:
NI-7 Diffusion-weighted imaging for monitoring acute response and recurrence after photodynamic therapy in malignant gliomas
Authors: Fujita Yuichi , Nagashima Hiroaki , Tanaka Kazuhiro , Hashiguchi Mitsuru , Itoh Tomoo , Sasayama Takashi 
Published: December 2021

Abstract

Background
Photodynamic therapy (PDT) subsequent to surgical tumor removal is a novel light-activated localized treatment for malignant glioma. Although PDT provides effective local control, even PDT cannot completely suppress local recurrence of malignant glioma. We previously reported that the acute response of malignant glioma to PDT could be detected as linear hyperintense signals on diffusion-weighted imaging (DWI) and a decline in apparent diffusion coefficient (ADC) values that were asymptomatic and transient. However, their long-term clinical significance has not yet been examined. This study aimed to clarify the link between the hyperintense signal on DWI as an acute response and recurrence after PDT in malignant glioma.

Methods
Thirty consecutive patients (16 men, 14 women; median age 60.5 years) underwent PDT for malignant glioma at our institution between 2017 and 2020. We analyzed signal changes on DWI after PDT and the link between these findings and the recurrence pattern.

Results
In all patients, linear hyperintense signals of 5–7 mm on DWI were detected at the surface of the resected cavity from day 1 after PDT. These changes matched the PDT-irradiated area and disappeared in about 30 days without any neurological deterioration. Of the 30 patients, 19 (63%) exhibited recurrence: local recurrence in 10 (33%), distant recurrence in 1 (3%), and dissemination in 8 (27%). All local recurrences arose from areas that did not show a hyperintense signal on DWI obtained on day 1 after PDT. Patients with distant recurrence or dissemination tended to have uninterrupted hyperintense signal on DWI obtained on day 1 after PDT.

Conclusion
The local recurrence in malignant glioma after PDT occurred in the areas without hyperintense signal on DWI as the acute response to PDT. This characteristic finding could aid in the monitoring of not only PDT-irradiated area but also local recurrence site after PDT.
NI-13 Prediction of outcome at the time of discontinuing TMZ-adjuvant therapy in IDH-mutant lower grade glioma using 11C-methinine PET
Authors: Beppu Takaaki , Sato Yuichi , Sasaki Toshiaki , Terasaki Kazunori , Iwaya Takeshi , Ogasawara Kuniaki 
Published: December 2021

Abstract
Purpose: This study aimed to clarify whether positron emission tomography with 11C-methyl-L-methionine (11C-met PET) can predict consequential outcomes at the time of discontinuing temozolomide (TMZ)-adjuvant chemotherapy in patients with residual isocitrate dehydrogenase gene (IDH)-mutant lower-grade glioma.Methods: In 30 patients showing residual lesions of IDH-mutant lower grade glioma (16 with diffuse astrocytoma and 14 with anaplastic astrocytoma), we performed 11C-met PET, and calculated the tumor-to-normal brain tissue ratio of standardized uptake values (SUVT/N) at the time of discontinuing TMZ-adjuvant chemotherapy. We determined cutoff values to predict tumor relapse using the receiver operating characteristic curve for various prognostic factors including age, Karnofsky performance scale, number of courses of therapy, residual tumor size, and SUVT/N. The promotor methylation status of O6-methylguanine-DNA methyl-transferase gene (MGMT) was assessed using methylation-specific polymerase chain reaction. Progression-free survival (PFS) was compared between groups divided by cutoff values. Uni- and multivariate analyses were conducted using log-rank testing and Cox regression analysis, respectively.Results: Univariate analysis identified MGMT methylation status (p = 0.04) and an SUVT/N of 1.27 (p = 0.02) as predictors of PFS after TMZ discontinuation. In multivariate analysis, both unmethylated MGMT and SUVT/N ≥ 1.27 remained as strong predictors of unfavorable outcome. Conclusion: The present study suggested that 11C-met PET allows prediction of outcomes comparable to MGMT promotor methylation status at the time of discontinuing TMZ-adjuvant chemotherapy in patients with residual IDH-mutant lower-grade glioma.
NI-15 Comparison of amide proton transfer imaging with perfusion imaging of using arterial spin-labeling for evidence of tumor cells in glioma
Authors: Yamauchi Takahiro , Kitai Ryuhei , Umeda Hideto , Tsukinowa Yu , Hagihara Ryota , Shibaike Yoshinori , Kawajiri Satoshi , Kidoguchi Masamune , Yamada Shinsuke , Isozaki Makoto , Arishima Hidetaka , Kodera Toshiaki , Kimura Hirohiko , Kikuta Ken-Ichiro 
Published: December 2021

Abstract
BACKGROUND: Infiltrative gliomas show cerebral edema and tumor infiltration as areas of hyperintensity in FLAIR image. Amide proton transfer (APT) and cerebral blood flow (CBF) are useful for evaluating the tumor invasion. In this study, arterial spin-labeling (ASL)-CBF and APT were compared to determine which method was superior for predicting tumor infiltration in gliomas, pathologically. METHODS: Fifteen specimens from 5 glioma patients with confirmed selective sampling were obtained. Based on APT signal intensity (SI), regions of interests (ROIs) were selected for biopsy. Same regions of these ROIs were marked on the same slice of ASL imaging. Samples were pathologically assessed for cell density and vessel density. APT SI and ASL-CBF were analyzed for each specimen. RESULTS: APT signal intensity (SI) showed a strong correlation with cell density (R = 0.887, P &lt; 0.0001). ASL-CBF showed no correlation with cell density (R = 0.240; P = 0.3836) but a correlation with vessel density (R = 0.697; P = 0.0038). In linear regression analysis, APT SI showed a positive relationship with cell density (R2 = 0.787, P &lt; 0.0001, linear regression; y = 30.70 + 6.24E-3*x). CONCLUSIONS: APT imaging was superior in predicting cellular proliferation than ASL-CBF and a powerful predictor of cell density. APT imaging allowed revelation of novel clues reflecting tumor proliferation in brain tumor; to date, this is the first known report to assess cell density among various brain tumors and conditions after treatment.
NQPC-10 (Rare) Cancer patients’ unmet needs (patient-focused healthcare needs) survey
Authors: Gatellier Laureline , Moue Yuko , Matsuda Tomohiro 
Published: December 2021

Abstract
Background: Rare Cancers Japan (RCJ) consists of members of 20 rare cancer patient groups and individual rare cancer patients, including the Japan Brain Tumor Alliance (JBTA), the Pediatric Brain Tumor Network, and the DIPG Symposium Organizing Committee, and aims to solve the challenges of rare cancers. RCJ, together with the National Cancer Center Japan and the Japan Federation of Cancer Patient Groups is currently conducting a survey to clarify unmet needs of patients, as a follow-up survey to surveys conducted in 2018. Since then, a major paradigm shift happened in Japan, with the advent of genomic medicine and development of new treatments. This study plans to identify the latest unmet needs of cancer patients and to clarify the differences between cancer types to provide data for the improvement of healthcare systems.Purpose: Focusing on unmet needs of cancer patients, we conduct an online questionnaire survey of a total of 1,600 cancer patients (including brain tumor patients) regarding the following endpoints (1) detection and diagnosis, (2) treatment, (3) genomic medicine (access to genetic mutation testing), (4) clinical trials, (5) necessary information, medical care and support systems and (6) quality of life. The collected information will be analyzed to clarify the needs of patients and the nature of patient-centered healthcare. Method: The survey will be administered online, including a mix of open-ended and multiple-choice questions. The total number of questions, including respondent demographics, is 38, and the time required to answer them is expected to be between 15 and 20 minutes. Data analysis will take into account cancer type of cancer, gender, age group and region of residence of the respondent.Expected results: By February 2022, the results of the survey are expected to be available, as basis of discussion to improve brain tumor treatment and follow up, from a multidisciplinary perspective.
MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor
Authors: Mitsuya Koichi , Deguchi Shoichi , Muto Manabu , Yasui Kazuaki , Onoe Tsuyoshi , Ogawa Hirofumi , Hayashi Kenji , Asakura Hirofumi , Harada Hideyuki , Hayashi Nakamasa 
Published: December 2021

Abstract
BACKGROUND: Large brain metastases which require resection are treated with surgery followed by whole brain radiation therapy or postoperative stereotactic radiosurgery (SRS). Recently a novel strategy using neoadjuvant stereotactic radiosurgery (Na-SRS) followed by surgery was reported, demonstrating lower rates of postoperative leptomeningeal dissemination (LMD) and symptomatic radiation necrosis (RN). We treated with neoadjuvant fractionated stereotactic radiotherapy (Na-fSRT) followed by surgery for large brain metastasis with piecemeal resection.
METHODS: Twelve patients received Na-fSRT followed by surgery between July 2019 and April 2021. Na-fSRT dose was based on lesion size and was standard dosing. Surgery generally followed within 7 days after radiotherapy.
RESULTS: The mean age was 68 years (51–79). Sixteen men and five women. Mean follow-up period was 8.5 months (1–24.9). Primary were lung; 10 (NSCLC; 9, SCLC (recurrence); 1), esophagus; 3, colon; 2, melanoma; 2, kidney; 2 (recurrence1), uterus body; 1, and liver; 1. The median maximum tumor diameter was 3.6 cm (2.6–4.9). Median PTV, GTV volume were 21.7ml, 15.5ml, respectively. The median fSRT dose was 30Gy/5fr, and the median time from fSRT to surgery was 4 days (1–7). As preoperative adverse event, intracranial hypertension and partial seizure grade 2 (CTCAE ver.5) were occurred, but controlled with steroid and osmotic diuretics and anticonvulsant. Grade 3 and more adverse events were not occurred. Gross total removal was performed in 95.2%. Event cumulative incidence as follows: cavity local recurrence 4.8% (subtotal removal case); distant brain failure 33%; LMD 4.8%; and symptomatic RN 0%. The median intracranial progression free survival was 7 months, and median overall survival was 8.4 months.
CONCLUSIONS: Na-fSRT followed by piecemeal resection is safety and feasible, and may have therapeutic value for deep large brain metastasis and eloquent lesion. Further prospective investigations in multi-institutional settings are warranted.
MET-11 Recent advances in targeted therapies and immunotherapy for metastatic brain tumors
Authors: Ando Yuichi 
Published: December 2021

Abstract
This presentation outlines CQ2 of Chapter 2 from the forthcoming updated version of the Clinical Practice Guidelines for Brain Tumors, edited by the Society. These guidelines discuss chemotherapy and other drug therapies for metastatic brain tumors in adult patients. First, there is no noteworthy change in the principle of prioritizing local treatment of symptomatic metastatic brain tumors or those that require local treatment in the near future. However, with recent advances in molecular-targeted drugs and/or immune checkpoint inhibitors, many physicians now consider starting systemic treatment prior to local treatment of brain metastases, even in patients with solid tumors that were once considered insensitive to chemotherapy, given that their symptoms are well-controlled and do not require urgent treatment. In the treatment of non-small cell lung cancer (NSCLC), the molecular subtypes of metastatic brain tumors with EGFR mutations and ALK fusion genes have yielded favorable responses to molecular-targeted drugs. Because small molecule drugs are well delivered to the central nervous system, systemic drug therapy with such targeted drugs is commonly selected for patients with untreated metastatic brain tumors. A recent phase II trial has shown the effectiveness of anti-PD-1 antibody pembrolizumab monotherapy for metastatic brain tumors from NSCLC. Because untreated metastatic brain tumors from renal cell carcinoma are prone to bleeding, local treatment of brain metastases should be prioritized before systemic treatment, even if the patient is asymptomatic. Regardless of BRAF mutation status, immune checkpoint inhibitors alone or in combination (nivolumab and ipilimumab) are effective against malignant melanoma with brain metastases; moreover, a combined treatment with BRAF and MEK inhibitors is effective against BRAF mutation-positive malignant melanoma with brain metastases. A novel HER2 inhibitor, tucatinib (unapproved), is expected to be effective against metastatic brain tumors from HER2-positive breast cancer.
MNG-2 Meningioma with aseptic meningitis
Authors: Nakajima Hideki , Tsuchiya Takuro , Shimizu Shigetoshi 
Published: December 2021

Abstract
The patient, a woman in her seventies, visited the Department of Neurology at our hospital one month ago with transient right hemiparesis, and was referred to our department because a CT scan showed a 4cm extramedullary lesion in the left convexity. She was judged to have symptomatic epilepsy associated with the lesion and was started on antiepileptic drugs. The lesion showed low signal on T1WI, equal signal on T2WI, and homogeneous contrast on Gd contrast T1WI, suggesting a meningioma, but the surrounding left frontal lobe subarachnoid space was also contrasted, suggesting the possibility of seeding or other diseases. After that, the contrast area of the subarachnoid space increased in a short period of time, and the control of epileptic seizures was poor. Preoperative spinal fluid examination showed an elevated cell count and findings of aseptic meningitis. A left parietal craniotomy was performed to remove the extramedullary tumor as much as possible. The subarachnoid space of the left frontal lobe adjacent to the tumor was covered with extensive pale yellow apparently abscess-like tissue. The pathological diagnosis of the extramedullary tumor was angiomatous meningioma (WHO Grade 1), and the pale yellow tissue that filled the subarachnoid space was necrotic tissue containing neutrophils and no tumor component. IgG4 was positive in about 10% of the tumor. The postoperative course of the patient was good, the contrast area of the left frontal lobe subarachnoid space was reduced on MRI, aseptic meningitis was improved, and she was discharged home with no neurological deficits. The patient has been under outpatient observation for 2 years without recurrence of aseptic meningitis or appearance of contrast-enhancing lesions in the subarachnoid space. This case is thought to be a possible IgG4-related disease, and we report it with a discussion of the literature.
CS-5 A case of anaplastic pleomorphic xanthoastrocytoma in the pineal region
Authors: Nakayama Noriyuki , Yamada Ryuta , Yamada Tetsuya , Iwama Toru 
Published: December 2021

Abstract
Tumors in the pineal gland are rare tumors that account for about 0.3% of all brain tumors and have various histological types of tumors develop with germinoma, pineocytoma, and pineoblastoma in that order. On the other hand, pleomorphic xanthoastrocytoma (PXA) is a rare tumor of less than 0.2% and frequently occurs in supratentorial cerebral surface of children and young adults.A case was a 61-year-old man whose pineal tumor was found due to visual disturbance. MRI showed a 23 mm-sized lesion with cysts and inhomogeneous enhancement in the pineal gland. Partial calcification was observed, but there was no non-communicating hydrocephalus, and no increase in HCG-β and AFP with blood sampling. A midline suboccipital craniotomy was performed in the sitting position, a head-up surgery was performed using a 4K / 3D video microscope system (ORBEYE exoscope, Olympus) by the infratentorial supracerebellar approach (ITSCA). The bridging veins and precentral cerebellar vein were dissected to expose the posterior surface of the tumor, and internal decompression was performed. For the complication of air embolism, artificial cerebrospinal fluid was sprayed, and the bilateral internal jugular veins were compressed to confirm the inflow point. There was strong adhesion to the Rt vein of Rosenthal, and the site was removed intracapsularly. Finally, subtotal resection was performed with remaining the upper part of the tumor, a blind lesion behind the Vein of Galen. Vertical gaze palsy occurred after this operation, but it gradually improved over time. Tumor showed pathologically remarkable polymorphism, poor microvascular proliferation and necrosis, but mitotic figures 4–5 / 10HPF, MIB-1 index 10%, GFAP positive, no BRAF V600E mutation. There are few reports of PXA occurring in the pineal gland, and this case is the sixth case. It is also the first report for pineal tumors using ORBEYE through ITSCA in the sitting position.
COT-13 Luminance analysis of 5-aminolevulinic acid using Image J for malignant brain tumor
Authors: Kon Takashi , Kobayashi Yusuke , Sato Yosuke , Shimizu Katsuyoshi , Mizutani Tohru 
Published: December 2021

Abstract
Purpose: For malignant brain tumor surgery, photodynamic diagnosis (PDD) with 5-aminolevulinic acid (5-ALA) is useful for maximal removal of the tumor. Although it has the advantage of identifying the presence or absence of residual tumors during surgery, there are variations in positive rates, and the classification is limited, based on visual inspection such as Stummer’s classification (strong, vague, none). We analyzed the luminance of positive findings using software Image J for brain tumor surgery using 5-ALA, and we report the results. Materials and Methods: From April 2018 to March 2021, 31 patients with suspected malignant glioma before surgery were included. Intraoperative 5-ALA positive findings were analyzed by software Image J (Wayne Rasband: NIH), the luminance was measured with a histogram, and compared the maximum luminance titer. Results: Among the positive cases, the average maximum luminance value for malignant glioma was 101 (50–168), which consisted of 11 cases of Glioblastoma, 1 case of Oligodendroglioma, and 1 case of anaplastic astrocytoma. The average maximum brightness of metastatic brain tumors is lower than that of malignant gliomas, even if they are visually strong, 83.5 (28–121). Conclusions: Even if it is visually strong in the conventional Stummer classification, it may be possible to classify in detail by analyzing luminance with Image J. In addition, more objective index is necessary to classify the vague findings.
COT-18 Trends in Primary Brain Tumors in Kumamoto Prefecture with Declining Birthrate and Aging Population - Kumamoto Prefecture Brain Tumor Epidemiological Survey
Authors: Shinojima Naoki , Itoyama Takashi , Mukasa Akitake 
Published: December 2021

Abstract
Backgrounds: The demographic characteristics of Kumamoto Prefecture are that there is little population movement and the total population remains constant at about 1.8 million, but in recent years the birthrate is declining and the population is aging. We have been conducting the Kumamoto Prefecture Brain Tumor Epidemiological Survey since 1989 in cooperation with neurosurgical institutions in the prefecture. In this study, we examined whether recent demographic changes have affected the incidence of primary brain tumors (BT). Methods: Patients with primary BT were collected annually from 44 institutions in Kumamoto Prefecture (as of 2020), and the number of incidences per 100,000 population was calculated for each BT for each year, excluding patients living outside the prefecture and duplicate cases. Results: The total number of primary BT was 11441 (top 3: meningioma 40%, pituitary adenoma 17%, glioma 17%). Of 4261 men with primary BT, the top 3 were meningioma (27%), glioma (23.7%), and pituitary adenoma (18.4%)), and 7180 women (top 3: meningioma (47.7%), pituitary adenoma (16.2%), and glioma (12.9%)). The number of primary BT increased every year, and the incidence increased significantly when comparing 1989–2004 and 2005–2020 (13.6 vs. 25.0/100,000, p&lt;0.000001). Typical brain tumors (meningioma, pituitary adenoma, glioma, schwannoma, malignant lymphoma) also increased year by year, especially asymptomatic meningioma. The median age of asymptomatic meningiomas was significantly higher than that of symptomatic meningiomas (69 vs. 65 years, p&lt;0.0001). Gliomas increased significantly in the later stages compared with the early stages in children (0–14 years) and the elderly (65 years and older). Conclusion: Our results suggest that an increase in the number of BT such as glioblastoma, which are more common in the elderly, as well as an increase in the number of opportunities for intracranial examinations in the aging of the population may be responsible for the increased incidence of primary BT.
Viewing the American West as a Chicana in China
Authors: Montoya María E 
Published: December 2021

Abstract
In both scholarly work and popular imagination, the American West is the final destination of migrant from Europe and Mexico. The stories of those migrants, however, obscure the first migration (12,000 BP) from Asia into North America. That migration across the now-submerged land bridge of Beringia ended humanity’s millennia-long journey across the globe that originated in Africa more than 50,000 years earlier. Using two examples, this essay reflects on how the Asian origins of the first Americans have been transformed into myths that conceal humanity’s migratory nature. First, in Chinese Communist propaganda, those origins are transformed into the myth of Peking Man as a branch of humanity originating in China rather than Africa. Second, in the writing of Rudolfo Anaya, those Asian origins are transformed into the myth of homogenous “Brown Brothers” united against white imperialists. Rather than rely on a myth of racial unity in some original homeland, this essay urges reliance on the shared experience of migration and home-making in hostile environments as the true source of our common humanity. Anaya’s Golden Carp, symbol of the life-giving fierce of water in an arid environment, captures this common human predicament stretching from Tibet and Xinjiang to New Mexico, epitomizing the American West as the place where humanity has been reunited, the home to the last wanderers of the human race.